CrowdStrike Holdings (CRWD) delivered mixed results in Q1 FY2027 on revenue of $1.4B versus the $1.4B estimate (+25.6% YoY) and EPS of $1.10. The next CrowdStrike Holdings (CRWD) earnings date is Sep 1, 2026. Below is the full CrowdStrike Holdings earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
$1.4B (vs $1.4B est · +1.7% surprise · +25.6% YoY)
EPS
$1.10 (vs $1.07 est · +2.8% surprise · -125.0% YoY)
Share price
$193.98 (+0.4%)
Market cap
$197.5B
CrowdStrike Holdings (CRWD) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q2 2026
$1.4B vs $1.4B est
$1.10 vs $1.07 est
+2.8%
-6.5%
Mixed
Q1 2026
$1.3B vs $1.3B est
$0.28 vs $0.27 est
+2.8%
+5.9%
Mixed
Q4 2025
$1.2B vs $1.2B est
$0.24 vs $0.23 est
+2.2%
+4.0%
Mixed
Q3 2025
$1.2B vs $1.1B est
$0.23 vs $0.21 est
+11.7%
+5.8%
Mixed
Q2 2025
$1.1B vs $1.1B est
$0.18 vs $0.20 est
-9.7%
-3.9%
Mixed
Q1 2025
$1.1B vs $1.0B est
$0.26 vs $0.21 est
+20.2%
-4.5%
Beat
Q4 2024
$1.0B vs $982.8M est
$0.93 vs $0.20 est
+359.3%
-4.4%
Beat
Q3 2024
$963.9M vs $960.0M est
$0.26 vs $0.24 est
+7.2%
+0.7%
Mixed
What you'll find
Next CrowdStrike Holdings (CRWD) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment CrowdStrike Holdings reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in CrowdStrike Holdings (CRWD)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is CrowdStrike Holdings's next earnings date?
CrowdStrike Holdings's (CRWD) next scheduled earnings date is Sep 1, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did CrowdStrike Holdings (CRWD) beat or miss earnings?
In Q1 FY2027, CrowdStrike Holdings (CRWD) posted mixed results — revenue of $1.4B versus the $1.4B estimate (+1.7% surprise) and EPS of $1.10 versus $1.07 expected (+2.8% surprise). Magnisto decodes every CrowdStrike Holdings (CRWD) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does CrowdStrike Holdings beat earnings estimates?
Over its last 8 reported quarters, CrowdStrike Holdings (CRWD) beat Wall Street EPS estimates 7 times, most recently a mixed result in Q2 2026. Magnisto tracks every CrowdStrike Holdings (CRWD) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does CrowdStrike Holdings stock move after earnings?
Over its last 8 quarterly reports, CrowdStrike Holdings (CRWD) moved an average of ±4.5% the day after earnings — ranging from -6.5% (Q2 2026) to +5.9% (Q1 2026). The stock rose after 4 of those 8 reports and fell after 4. Heading into its next report on Sep 1, 2026, options-implied volatility is pricing in a move of roughly ±20.3% (derived). Magnisto tracks the realized post-earnings move for every CrowdStrike Holdings (CRWD) quarter alongside the beat/miss verdict — past moves don't predict the next one.
What is the forecast for CrowdStrike Holdings (CRWD) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for CrowdStrike Holdings (CRWD), anchored to the current $193.98 share price, so you can weigh the bull, base and bear cases for CrowdStrike Holdings side by side.
Is CrowdStrike Holdings (CRWD) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether CrowdStrike Holdings fits your own thesis and risk profile. This is research, not investment advice.